University of Santo Tomas Hospital Trials

University of Santo Tomas Hospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Mejia, Michael

KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting

100

NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg

NovoCure GmbH, Merck Sharp & Dohme LLC

Non-small Cell Lung Cancer

07/24

12/26

Souza, Pedro Augusto M

NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated

Europe, US, RoW

Daxdilimab, Placebo (Normal Saline)

Amgen, Horizon Therapeutics Ireland DAC

Lupus Nephritis

01/24

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Navarra, Sandra

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

APLCLLDAS, NCT03138941: Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

Recruiting

N/A

5000

Japan, RoW

Monash University, Flinders Medical Centre, Adelaide, AUSTRALIA, St. Vincent's Hospital, Melbourne, AUSTRALIA, Royal Adelaide Hospital, Adelaide, AUSTRALIA, University of New South Wales, Sydney, AUSTRALIA, People's Hospital, Peking University Health Science Center, Beijing, CHINA, Peking University First Hospital, Beijing, CHINA, The University of Hong Kong, HONG KONG, University of Padjadjaran, Bandung, INDONESIA, Tokyo Women's Medical University, JAPAN, University of Occupational and Environmental Health, JAPAN, Keio University, JAPAN, Hanyang University Hospital for Rheumatic Diseases, REPUBLIC OF KOREA, University of Santo Tomas Hospital, Philippines, National University Hospital, Singapore, Tan Tock Seng Hospital, Chang Gung Memorial Hospital, Taichung Veterans General Hospital, Chiang Mai University Hospital, THAILAND, Middlemore Hospital, New Zealand, North Shore Hospital, Auckland, NEW ZEALAND, Auckland District Health Board, Auckland, NEW ZEALAND, Teaching Hospital Kandy, SRI LANKA, University of the Philippines, Philippines

Systemic Lupus Erythematosus

12/27

12/32

Deboni, Luciane MÃ´nica

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Ye, Zhiming

NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED )

Recruiting

9000

RoW

Aspirin 100 mg Oral Tablet, Matching Placebo

Guangdong Provincial People's Hospital, The George Institute

CKD (Chronic Kidney Disease) Stage 5D

09/26

12/26

NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Recruiting

2/3

216

RoW

B007, Cyclosporin Capsules

Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd

Primary Membranous Nephropathy

12/26

NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)

Active, not recruiting

RoW

efgartigimod IV, Placebo

argenx, Zai Lab (Shanghai) Co., Ltd.

Lupus Nephritis

07/25

09/25

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not yet recruiting

1/2

RoW

SCTC21C

Sinocelltech Ltd.

IgA Nephropathy

09/27

03/29

DKTAVG, NCT06503692: Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis

Recruiting

N/A

140

RoW

DKutting PTA Scoring Balloon Dilatation Catheter, Scoring Balloon, Peripheral Balloon Catheter

DK Medical Technology (Suzhou) Co., Ltd.

Arteriovenous Graft Stenosis

12/26

NCT05190848: Correlation of Microbiome and Metabonomics With IgA Nephropathy

Recruiting

N/A

600

RoW

Guangdong Provincial People's Hospital

IgA Nephropathy

12/24

NCT05188885: A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases

Recruiting

N/A

90000

RoW

Guangdong Provincial People's Hospital

Chronic Kidney Disease

12/26

12/28

AraÃºjo, Maria das GraÃ§as

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Zhang, Fan

ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules

Not yet recruiting

426

RoW

regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo

Xintian Pharmaceutical

Thyroid Nodule

07/25

07/28

NCT05812014: Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older

Recruiting

9800

RoW

SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution

AIM Vaccine Co., Ltd., LiveRNA Therapeutics Inc., Ningbo Rongan Biological Pharmaceutical Co. Ltd.

SARS-CoV-2

03/24

06/24

RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（）

Recruiting

2105

RoW

14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management

Capital Medical University

Acute Ischemic Stroke, Anterior Circulation Brain Infarction

11/26

02/27

INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

Not yet recruiting

120

RoW

bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C

Huashan Hospital, Beijing Chest Hospital

Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis

06/27

INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Recruiting

186

RoW

Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB

Beijing Chest Hospital, National Medical Center for Infectious Diseases

Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

10/26

12/26

NCT02029937: High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia

Recruiting

1300

US, RoW

Proflavine, high resolution imaging, Proflavine hemisulfate

Anandasabapathy, Sharmila, M.D., William Marsh Rice University, Baylor College of Medicine

Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia

12/21

NCT05939648: A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Active, not recruiting

450

RoW

SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline

AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co., Ltd.

SARS-CoV-2

11/23

12/24

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

NCT05939596: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Active, not recruiting

RoW

SARS-CoV-2 Bivalent mRNA Vaccine, LVRNA021, Saline

AIM Vaccine Co., Ltd., First Affiliated Hospital Bengbu Medical College

SARS-CoV-2

09/23

08/24

NCT06773286: Combining Spinal Cord Transcutaneous Stimulation and Activity-based Training in Inpatient Rehabilitation to Facilitate Upper Limb Function of Individuals with Acute to Subacute Cervical Spinal Cord Injury

Recruiting

N/A

Active Stimulation, Sham, Training only

Kessler Foundation

Spinal Cord Injury Cervical

12/25

NCT05845372: Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

Not yet recruiting

N/A

2592

RoW

Nanfang Hospital of Southern Medical University, The Fourth Affiliated Hospital of Guangzhou Medical University, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huadu District People's Hospital of Guangzhou, Dongguan donghua hospital, Sinopharm North Hospital, Heyuan people's Hospital, Hainan People's Hospital, Hainan Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Second Hospital University of South China, Dongguan People's Hospital, Yueyang People's Hospital

Acute Ischemic Stroke

01/27

NCT05914272: Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction

Not yet recruiting

N/A

2592

RoW

Osmotic drugs

Nanfang Hospital of Southern Medical University, The Second Hospital University of South China, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, The Fourth Affiliated Hospital of Guangzhou Medical University, Dongguan People's Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Hainan Traditional Chinese Medicine Hospital, Hainan People's Hospital, Sinopharm North Hospital, Huadu District People's Hospital of Guangzhou, Guangdong Provincial Hospital of Traditional Chinese Medicine

Stroke

01/27

Oliveira, Rodrigo Correa

NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated

Europe, US, RoW

Daxdilimab, Placebo (Normal Saline)

Amgen, Horizon Therapeutics Ireland DAC

Lupus Nephritis

01/24

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

BEOD, NCT05859022: Metabolic Effects of Bariatric Arterial Embolization vs Bariatric Surgery

Recruiting

N/A

Europe

Roux-en-Y gastric By-pass (RYGB) surgery, Bariatric Arterial Embolization (BAE) procedure

Universidade Nova de Lisboa, cruz vermelha hospital

Obesity, Type2diabetes, Bariatric Surgery Candidate, Metabolic Disease

08/25

10/25

Bacci, Marcelo R

ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting

404

Europe, Canada, Japan, US, RoW

Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo

Chinook Therapeutics, Inc.

IgA Nephropathy, Immunoglobulin A Nephropathy

12/26

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Recruiting

320

Europe, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Type 2 Diabetes

09/26

10/26

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting

2750

Europe, Canada, RoW

Spironolactone 25Mg Tablet, Placebo Oral Tablet

Population Health Research Institute, Canadian Institutes of Health Research (CIHR)

Endstage Renal Disease

07/25

04/26

VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting

778

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Crohn's Disease

11/24

12/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

NCT04801017: A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Not yet recruiting

RoW

OT-101, Trabedersen, Artemisinin, ArtiVeda, Placebo, Normal saline

Oncotelic Inc.

COVID-19

08/21

10/21

NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated

Europe, US, RoW

Daxdilimab, Placebo (Normal Saline)

Amgen, Horizon Therapeutics Ireland DAC

Lupus Nephritis

01/24

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Huang, Anbin

NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Recruiting

186

RoW

Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Systemic Lupus Erythematosus, SLE

08/25

05/26

NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting

296

RoW

Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control

Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan

Connective Tissue Diseases, Thrombocytopenia

12/25

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Paschoalin, Raphael Pereira

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

NCT05540665 / 2022-001377-31: Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Terminated

Europe, US, RoW

Daxdilimab, Placebo (Normal Saline)

Amgen, Horizon Therapeutics Ireland DAC

Lupus Nephritis

01/24

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Lokin, Johnny K

PNA1DB-Stroke, NCT04972058: Philippine Neurological Association One Database - Stroke

Completed

N/A

14800

RoW

Philippine Neurological Association

Transient Ischemic Attack, Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Cerebral Venous Thrombosis

08/24

Bacorro, Warren

HYACINCT, NCT05210270: HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy

Not yet recruiting

1/2

Hypofractionation, Nodal simultaneous integrated boost, Brachytherapy

University of Santo Tomas Hospital, Philippines, Philippine Council for Health Research & Development

Locally Advanced Cervical Carcinoma

03/28

03/30

CECIL, NCT05701735: Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer

Recruiting

N/A

RoW

CECIL Patient Decision Aid, Decision Support Intervention

University of Santo Tomas Hospital, Philippines, University of Santo Tomas - Graduate School, University of Santo Tomas - Faculty of Medicine and Surgery, University of Santo Tomas Hospital - Benavides Cancer Institute, Philippine Council for Health Research & Development, Manila Doctors Hospital, Our Lady of Lourdes Hospital

Locally Advanced Cervical Carcinoma

09/24

12/24

Castillo, Ma Rosario Irene D

NCT05280821: Alternate Day vs. Daily Iron Supplementation in Iron Depleted Women in the Philippines

Terminated

N/A

RoW

daily ferrous sulfate, alternate day ferrous sulfate

Swiss Federal Institute of Technology, St. Luke's Medical Center, University of Oxford

Iron-deficiency

11/22

Ortin, Teresa Sy

CECIL, NCT05701735: Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer

Recruiting

N/A

RoW

CECIL Patient Decision Aid, Decision Support Intervention

Locally Advanced Cervical Carcinoma

09/24

12/24

Gonzalez, Gil

FUEL, NCT06010784: 'Food, Fun, Fresh, Family' Program for Healthy Eating and Growth for Elementary-age Children.

Active, not recruiting

N/A

119

Family support, BGCAA's after-school program with CATCH curriculum

University of Texas at Austin, Boys & Girls Clubs of the Austin Area

Diet, Healthy Growth

04/24

07/24

CECIL, NCT05701735: Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer

Recruiting

N/A

RoW

CECIL Patient Decision Aid, Decision Support Intervention

Locally Advanced Cervical Carcinoma

09/24

12/24

Ellano, Joshua Nathaniel V

NCT05797766: Efficacy Trial of Fluid Distribution Timetable

Completed

RoW

Fluid Distribution Timetable

University of Santo Tomas, University of Santo Tomas Hospital

End-stage Renal Disease

04/23

05/23

Paiva, Paula

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Carneiro, Tainá

PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended

279

Europe, US, RoW

zetomipzomib, KZR-616, placebo, matching placebo

Kezar Life Sciences, Inc.

Lupus Nephritis

05/26

07/26

Amparo, Genalin

CECIL, NCT05701735: Decision Aid for Chemotherapy in Cisplatin-Intolerant Patients With Locally Advanced Cervical Cancer

Recruiting

N/A

RoW

CECIL Patient Decision Aid, Decision Support Intervention

Locally Advanced Cervical Carcinoma

09/24

12/24



	Diseases Companies Products Productz Mechanisms of Action Sites